neuroscience-psychiatry-2018-posters

Journal of Neurology and Neurorehabilitation Research

Volume 3

Page 48

allied

academies

J u n e 2 8 - 2 9 , 2 0 1 8 | D u b l i n , I r e l a n d

Joint Event on

NEUROSCIENCE AND NEUROLOGICAL DISORDERS

PSYCHIATRY AND PSYCHOLOGICAL DISORDERS

International Conference on

PERSPECTIVES OF NANO-INTERVENTIONS IN EARLY DIAGNOSIS

AND TREATMENT OF ALZHEIMER’S DISEASE

Jerzy Leszek

Wroclaw Medical University, Poland

he lack of effective treatment for Alzheimer’s disease (AD) stems mainly from the incomplete understanding of AD causes. Currently

there are several hypotheses which try to explain the early molecular mechanisms of AD pathogenesis. The current pathophysiologic

approach is based on several common mechanisms of neurodegeneration, including accumulation of abnormal proteins tau and ABeta),

mitochondrial dysfunction, oxidative stress, impaired insulin signaling, calciumhomeostasis dysregulation, imbalanceof neurotransmitters,

early synaptic disconnection and late apoptotic cell death. Considering that AD is a multi-factorial disease with several pathogenic

mechanisms and pathways, a multifunctional nanotechnology approach may be needed to target its main molecular culprits. There are

still no effective treatments to prevent, halt or reserve AD. To very early diagnosis of AD we need to have affordable, ultrasensitive and

selective molecular detection methods. Nanomedicine as a biomedical and pharmaceutical application of nanotechnology for making

Nano carriers for instance dendrimers has shown great potential not only for diagnosis but the treatment of many CNS diseases such

AD. Ultra-low concentrations of protein biomarkers (eg.ADDL-amyloid-Beta-derived diffusible ligands) which have been implicated in the

pathogenesis of AD, is possible to detect, owing to carrier dendrimers. Dendrimers are polymeric molecules chemically synthesized with

well-defined shape size and nanoscopic physicochemical properties reminiscent of proteins. Recently an increasing number of studies

have been focused on the potential dendrimers to prevent aggregation and fibrillation of proteins involved in neurodegenerative disorders

such as AD. Some of dendrimers were demonstrated to cross blood-brain barrier, which legitimized research on these compounds as

potential drugs for neurological disorders. Recent our studies have revealed that dendrimers possess the intrinsic ability to localize in

cells associated with neuroinflammation (activated microglia and astrocytes) and thus can be used in neuroinflammation therapy. Above/

mentioned findings may be significance in the context of potential application of dendrimers as drug carriers or active compounds per se.

According to opinion the authors of this presentation, they are promising macromolecules for further investigations on their applicable in

neurodegenerative disorders, for instance AD.

J Neurol Neurorehabil Res 2018, Volume 3